More PRNewswire
View Older Stories View Newer Stories-
Sinch appoints Jonas Dahlberg as acting CEO to lead next phase of execution and growth
-
Everything-PR Names the 100 People Shaping What AI Engines Say
-
Carnegie Mellon Alumna Earns Tony Award for Best Musical
-
Winning firms will focus on what they can control, weather the rest, as triple-shock brakes private equity's latest revival --Bain & Company 2026 Midyear PE report
-
New IBM Study Finds CIOs and CTOs Face Growing AI Control Gap as Enterprise Deployment Scales
-
A Banner Year for Banks--and the Moment to Shift Gears on Growth, AI, and Innovation
-
For Decades, International Bodies Warned Germany Over Its Treatment of Scientologists
-
GIGABYTE Advances Motherboard Performance with AI-driven Technologies
-
HTX Launches "Appreciation Program" with Over $10 Million to Reward User Trust
-
Unisound Releases U2: A Native Agentic Large Model Built for Execution, Capable of Autonomously Decomposing and Completing 100+ Steps in Complex Real-World Workflows
-
Vi Appoints Spencer Honeyman as President, Global Growth
-
Xinhua Silk Road: Posidonia China Night provides high-level platform for int'l maritime exchange, cooperation
-
Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)
-
New Report "Early Bird" Maps Tech Investing for Asian Family Offices
-
GIGABYTE Advances Gaming Monitor Technologies with AI-optimized Visuals and Automatic OLED Protection
-
Anamana Incubator Targets Culturally Native Creators to Diversify Homogenized Micro-Drama Market
-
Uhale Adopts Quokka's Q-mast to Strengthen Application Security Testing
-
Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 an
-
OriCell's GPC3 CAR-T Receives NMPA Clearance for Confirmatory Phase II Trial in Late-Line Advanced Hepatocellular Carcinoma
-
Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance
-
VolitionRx Announces Pricing of $4.6 Million Public Offering
-
Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
-
Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications
-
AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
-
Lipid-Lowering Medications Demonstrate Cardiometabolic Benefits in Populations with High-Risk Diabetes
-
Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health
-
Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide
-
Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
-
MimiSilk Marks 12 Years of Advanced Care with New Product Launches and Anniversary Sale
-
Soules Kitchen Declares June 7th (6/7) the Official Day of Delightful Dinners
-
Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk unveils new data at ADA 2026
-
Bitty & Beau's Coffee Launches New Mini Cruiser Franchise Model
-
Vision Insurance After Retirement (2026): VSP Vision Care Named Leading Option for Retiree Eye Coverage by Expert Consumers
-
Bybit Launches IPO Express, Becoming One of First Centralized Crypto Exchanges to Offer Tokenized IPO Access, Starting With SpaceX
-
Looney Tunes™ Land Now Open at Six Flags Magic Mountain
-
"Tides & Voices" Salon: Consolidating the Foundation for Peace and Development in the South China Sea Through Dialogue and Cooperation
-
A New Era Begins: Cal Poly Unveils the John Madden Football Center
-
The American Diabetes Association Announces Winners of the Innovation Challenge
-
Texas Southern University Expands Elite Flight Training Fleet with New Twin-Engine Aircraft
-
Duke Energy offers tips to save energy and money as temperatures rise in the Carolinas
-
AMERICANS SWEEP ST. PETE AS RED BULL CLIFF DIVING WORLD SERIES MAKES HISTORIC FLORIDA DEBUT
-
From Bystanders to Heart Savers: MedStar Health CPR Training Event Puts Power to Save Lives in Community's Hands
-
Philippine Airlines to Join oneworld Alliance
-
Ramtech VP of Business Development Kelly Williams to Speak on Modular Construction Benefits in Panel Discussion at 2026 InterFace Houston Multifamily Conference
-
University of Phoenix researchers publish study examining doctoral students' attitudes toward AI chatbots and ChatGPT use in higher education
-
82% of Adults with Type 2 Diabetes Not on Insulin Improve Blood Glucose Levels with Continuous Glucose Monitoring
-
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and i
-
Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity
-
Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association's 2026 Scientific Sessions
-
/C O R R E C T I O N -- U.S. Postal Service/
